Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;20(1):2-14.
doi: 10.1016/j.jval.2016.11.005. Epub 2017 Jan 10.

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

Affiliations

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

John H Powers 3rd et al. Value Health. 2017 Jan.

Abstract

A clinician-reported outcome (ClinRO) assessment is a type of clinical outcome assessment (COA). ClinRO assessments, like all COAs (patient-reported, observer-reported, or performance outcome assessments), are used to 1) measure patients' health status and 2) define end points that can be interpreted as treatment benefits of medical interventions on how patients feel, function, or survive in clinical trials. Like other COAs, ClinRO assessments can be influenced by human choices, judgment, or motivation. A ClinRO assessment is conducted and reported by a trained health care professional and requires specialized professional training to evaluate the patient's health status. This is the second of two reports by the ISPOR Clinical Outcomes Assessment-Emerging Good Practices for Outcomes Research Task Force. The first report provided an overview of COAs including definitions important for an understanding of COA measurement practices. This report focuses specifically on issues related to ClinRO assessments. In this report, we define three types of ClinRO assessments (readings, ratings, and clinician global assessments) and describe emerging good measurement practices in their development and evaluation. The good measurement practices include 1) defining the context of use; 2) identifying the concept of interest measured; 3) defining the intended treatment benefit on how patients feel, function, or survive reflected by the ClinRO assessment and evaluating the relationship between that intended treatment benefit and the concept of interest; 4) documenting content validity; 5) evaluating other measurement properties once content validity is established (including intra- and inter-rater reliability); 6) defining study objectives and end point(s) objectives, and defining study end points and placing study end points within the hierarchy of end points; 7) establishing interpretability in trial results; and 8) evaluating operational considerations for the implementation of ClinRO assessments used as end points in clinical trials. Applying good measurement practices to ClinRO assessment development and evaluation will lead to more efficient and accurate measurement of treatment effects. This is important beyond regulatory approval in that it provides evidence for the uptake of new interventions into clinical practice and provides justification to payers for reimbursement on the basis of the clearly demonstrated added value of the new intervention.

Keywords: clinical trials; clinician-reported outcomes; end points; outcome assessments.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Direct to indirect assessments of treatment benefit. ADAS-COG, Alzheimer’s Disease Assessment Scale—Cognitive; ALS, amyotrophic lateral sclerosis; BPRS, Brief Psychiatric Rating Scale; COA, clinical outcome assessment; CT, computed tomography; ETDRS, Early Treatment Diabetic Retinopathy Study; EXACT-PRO, the EXAcerbaCTtions of chronic pulmonary disease tool; FVC, forced vital capacity; FEV1, forced expiratory volume in 1; FLU-PRO, InFLUenza Patient-Reported Outcome; HgbA1c, glycated hemoglobin; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; SDMT, Symbol Digit Modalities Test.

Comment in

References

    1. US Food and Drug Administration. [Accessed January 3, 2017];Clinical outcome assessment (COA): glossary of terms. 2016 Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentTools....
    1. Walton MK, Powers JH, III, Hobart J, et al. Clinical outcome assessments: conceptual foundation—Report of the ISPOR Clinical Outcomes Assessment—Emerging Good Practices for Outcomes Research Task Force. Value Health. 2015;18:741–52. - PMC - PubMed
    1. Aaronson N, Alonso J, Burnam A, et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11:193–205. - PubMed
    1. Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA. 2014;311:378–84. - PubMed
    1. Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305. - PMC - PubMed

LinkOut - more resources